Bridgebio Pharma Inc (BBIO)

05:58 AM

BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore (NASDAQ:BBIO) - Seeking Alpha

05:58 AM

03:59 AM

BridgeBio rises after late-stage trial win for dwarfism therapy - MSN

03:59 AM

03:03 AM

BridgeBio Pharma Is Maintained at Buy by Truist Securities - Moomoo

03:03 AM

02:13 AM

BridgeBio earnings on deck: Can Attruby sustain rapid growth? By Investing.com - Investing.com India

02:13 AM

02:08 AM

BridgeBio earnings on deck: Can Attruby sustain rapid growth? - Investing.com

02:08 AM

10:05 AM

BBIO Maintained by Truist Securities -- Price Target Raised to $102 - GuruFocus

10:05 AM

09:05 AM

BBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus

09:05 AM

08:12 AM

H.C. Wainwright reiterates BridgeBio Pharma stock rating on stable Vyndamax outlook - Investing.com Canada

08:12 AM

03:56 AM

BridgeBio gains amid report of settlement in Pfizer Vyndamax patent dispute - MSN

03:56 AM

Apr 28, 2026

BridgeBio launches ATTR-CM awareness campaign with Morgan Freeman By Investing.com - Investing.com South Africa

Apr 28, 2026

Apr 28, 2026

BridgeBio launches ATTR-CM awareness campaign with Morgan Freeman - Investing.com UK

Apr 28, 2026

Apr 28, 2026

BofA raises BridgeBio Pharma stock price target on Pfizer settlement clarity - Investing.com Canada

Apr 28, 2026

Apr 28, 2026

Raymond James reiterates BridgeBio stock rating on Vyndamax settlement By Investing.com - Investing.com Canada

Apr 28, 2026

Apr 28, 2026

Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $106 - Moomoo

Apr 28, 2026

Apr 28, 2026

BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update) - MSN

Apr 28, 2026

Apr 28, 2026

BBIO Reiterated by Mizuho -- Price Target Maintained at $106 - GuruFocus

Apr 28, 2026

Apr 28, 2026

Barclays sees Pfizer IP case progress as positive for BridgeBio stock - Investing.com Canada

Apr 28, 2026

Apr 28, 2026

BridgeBio (BBIO) Q2 2025 Earnings Transcript - The Globe and Mail

Apr 28, 2026

Apr 28, 2026

Barclays reiterates Overweight on BridgeBio Pharma stock at $157 By Investing.com - Investing.com Canada

Apr 28, 2026

Apr 28, 2026

RBC Capital reiterates BridgeBio Pharma stock rating on patent clarity By Investing.com - Investing.com Canada

Apr 28, 2026

Apr 28, 2026

William Blair reiterates BridgeBio stock rating after Pfizer settlement By Investing.com - Investing.com Canada

Apr 28, 2026

Apr 28, 2026

Mizuho reiterates BridgeBio Pharma stock rating on Vyndamax patent news By Investing.com - Investing.com Canada

Apr 28, 2026

Apr 28, 2026

Mizuho reiterates BridgeBio Pharma stock rating on Vyndamax patent news - Investing.com

Apr 28, 2026

Apr 28, 2026

BridgeBio (BBIO) Shares Surge Following Pfizer Patent Settlement - GuruFocus

Apr 28, 2026

Apr 28, 2026

Mizuho reiterates BridgeBio stock rating on patent settlement news By Investing.com - Investing.com Canada

Apr 28, 2026

Apr 28, 2026

BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update) (BBIO:NASDAQ) - Seeking Alpha

Apr 28, 2026

Apr 28, 2026

BBIO Stock Draws Bulls As Rare-Disease Pipeline Gains Steam - StocksToTrade

Apr 28, 2026

Apr 28, 2026

Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance

Apr 28, 2026

Apr 28, 2026

(BPRW) BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White - Black PR Wire

Apr 28, 2026

Apr 28, 2026

Morgan Freeman joins push on a heart disease often mistaken for heart failure - Stock Titan

Apr 28, 2026

Apr 27, 2026

Wells Fargo Maintains BridgeBio Pharma (BBIO) Overweight Recommendation - MSN

Apr 27, 2026

Apr 27, 2026

BridgeBio says new Attruby data adds to benefit in ATTR-CM - MSN

Apr 27, 2026

Apr 27, 2026

H.C. Wainwright reiterates BridgeBio stock rating on patent case developments - Investing.com Canada

Apr 27, 2026

Apr 27, 2026

BridgeBio Pharma gains as investors refocus on pipeline catalysts ahead of expected earnings - Quiver Quantitative

Apr 27, 2026

Apr 27, 2026

Piper Sandler reiterates BridgeBio stock rating on patent settlement By Investing.com - Investing.com Canada

Apr 27, 2026

Apr 27, 2026

H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100 - Moomoo

Apr 27, 2026

Apr 27, 2026

BridgeBio Pharma, Inc. (BBIO) Stock Analysis: A Deep Dive Into Its 37.18% Potential Upside - DirectorsTalk Interviews

Apr 27, 2026

Apr 27, 2026

BBIO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Apr 27, 2026

Apr 26, 2026

Barclays initiates coverage of BridgeBio Pharma (BBIO) with overweight recommendation - MSN

Apr 26, 2026

Apr 26, 2026

MSN Money - MSN

Apr 26, 2026

Apr 26, 2026

BridgeBio Pharma prices $550M convertible bond offering - MSN

Apr 26, 2026

Apr 26, 2026

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Apr 26, 2026

Apr 25, 2026

Is It Too Late To Consider BridgeBio Pharma (BBIO) After Its 101.8% One-Year Surge? - Yahoo Finance

Apr 25, 2026

Apr 25, 2026

There Are Early Signals Ahead of Tafamidis Trial As Analysts See Potential Upside for Pfizer (PFE) and BridgeBio Pharma (BIO) - Markets Herald

Apr 25, 2026

Apr 24, 2026

BridgeBio (NASDAQ: BBIO) schedules 2026 virtual meeting, pay and equity plan votes - Stock Titan

Apr 24, 2026

Apr 24, 2026

BridgeBio (BBIO) Shares Rise Following Positive Patent Settlemen - GuruFocus

Apr 24, 2026